Key result
A high-sensitivity cardiac troponin I level ≥2.3 ng/L was associated with clinically actionable coronary artery disease, with prediction further improved by normalizing for myocardial mass.
Why the study?
Current risk-based prevention pathways miss some individuals with silent coronary artery disease, and the relationship between high-sensitivity cardiac troponin I and silent coronary atherosclerosis remains incompletely understood.
Does high-sensitivity cardiac troponin I measurement detect clinically actionable coronary artery disease in adults undergoing coronary CT imaging?
Cohort (n=1,613)
Does high-sensitivity cardiac troponin I measurement detect clinically actionable coronary artery disease in adults undergoing coronary CT imaging?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It worked best in the people our risk calculators miss. In those with none of the four standard modifiable risk factors, a troponin above 2.3 carried roughly four-fold odds of actionable disease. And Sina’s insight to normalise troponin to age and renal function plus or minus left ventricular mass lifted discrimination from 0.64 to 0.81 — with a mechanism attached.”
High-sensitivity cardiac troponin I, especially when normalized to left ventricular mass, age, and renal function, can help detect clinically actionable silent coronary artery disease and optimize triage for CT imaging.
Coronary artery disease often develops silently before myocardial infarction, and current risk-based prevention pathways miss some individuals with clinically important disease, particularly those without standard modifiable cardiovascular risk factors. High-sensitivity cardiac troponin I is a blood biomarker of low-level myocardial injury, but its relationship to silent coronary atherosclerosis remains incompletely understood. Here we show, in 1,613 adults undergoing coronary computed tomography (CT) imaging, that low-level high-sensitivity cardiac troponin I is associated with clinically actionable coronary disease, defined by coronary calcium score ≥100, and with quantitative CT markers of plaque burden. A threshold of 2.3 ng l −1 enriched for actionable disease, especially in individuals without standard risk factors. Normalizing troponin for myocardial mass, age and renal function improved prediction and provided mechanistic insight into baseline troponin elevation in chronic coronary syndromes. A two-stage strategy using troponin before CT imaging increased diagnostic yield and reduced the number of scans required. Prospective validation is warranted before clinical implementation.
No takes yet. Share an insight, caveat, or question.
Fathieh et al. (2026) conducted a cohort in Stable coronary artery disease (n=1,613). High-sensitivity cardiac troponin I ≥2.3 ng/L vs. High-sensitivity cardiac troponin I <2.3 ng/L was evaluated on Clinically actionable coronary disease (coronary calcium score ≥100) (OR 2.77, 95% CI 2.23-3.46). A high-sensitivity cardiac troponin I level ≥2.3 ng/L was associated with clinically actionable coronary artery disease, with prediction further improved by normalizing for myocardial mass.
Synapse has enriched 10 related papers. Consider them for comparative context: